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AbstrAct
Current treatments for periodontitis (e.g., scaling/
root planing and chlorhexidine) have limited effi-
cacy since they fail to suppress microbial biofilms 
satisfactorily over time, and the use of adjunctive 
antimicrobials can promote the emergence of 
antibiotic-resistant organisms. Herein, we report 
the novel application of nitric oxide (NO)-releasing 
scaffolds (i.e., dendrimers and silica particles) as 
anti-periodontopathogenic agents. The effective-
ness of macromolecular NO release was demon-
strated by a 3-log reduction in periodontopathogenic 
Aggregatibacter actinomycetemcomitans and 
Porphyromonas gingivalis viability. In contrast, 
Streptococcus mutans and Streptococcus sanguinis, 
caries-associated organisms, were substantially 
less sensitive to NO treatment. Both dendrimer- 
and silica-based NO release exhibited substan-
tially less toxicity to human gingival fibroblasts at 
concentrations necessary to eradicate periodonto-
pathogens than did clinical concentrations of 
chlorhexidine. These results suggest the potential 
utility of macromolecular NO-release scaffolds as 
a novel platform for the development of periodon-
tal disease therapeutics.
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Oral care comprises a significant fraction of health care costs in the United States, with $104.8 billion devoted to dental services in 2010 (Ebersole 
et al., 2012). A considerable portion of these expenses is attributed to peri-
odontal disease caused by dental plaque biofilms. Approximately 30% of the 
US population is afflicted by periodontitis (Kandelman et al., 2012). Left 
unmanaged, periodontitis can result in tooth loss and has been associated 
with increased risk for systemic conditions such as cardiovascular disease and 
stroke (Cobb, 2008; Sen et al., 2013).
The current “gold standard” non-surgical periodontal treatment is scaling 
and root planing (SRP). However, even successful treatment via SRP is 
accompanied by a high probability of reinfection, with periodontal surgery to 
reduce periodontal pockets as a likely treatment outcome (Cobb, 2008). Other 
non-surgical treatments for periodontal diseases, such as the use of chlorhex-
idine (CHX), have undesirable side effects, including altered taste, discolor-
ation of the mouth, and mucosal irritation (Charbonneau and Snider, 1997; 
Gürgan et al., 2006). In combination, CHX (0.2% w/w) with SRP does not 
significantly affect microbial composition compared with SRP alone. Quiryen 
et al. suggested that CHX treatment should be re-evaluated as an adjunct to 
SRP periodontal therapy (Quiryen et al., 2000). While the use of antibiotics 
(e.g., minocycline and tetracycline) represents a possible adjunct to SRP, and 
local drug delivery systems can improve clinical and microbial outcomes 
(Williams et al., 2001), their systemic use has undesirable side effects (e.g., 
antibiotic resistance, pseudomembranous colitis) (Radvar et al., 1996; Kinane 
and Radvar, 1999). The development of alternative treatments for periodonti-
tis thus remains an important area of current oral health care research.
Nitric oxide (NO) is a reactive, gaseous radical produced endogenously 
during the immune response to invading organisms (DeGroote and Fang, 
1999). For example, oral mucosal epithelial cells generate NO in response to 
bacteria and pro-inflammatory stimuli initiated upon the deposition of dental 
plaque (Carossa et al., 2001). While exogenous NO has been utilized as an 
antimicrobial agent with no previously observed resistance (Privett et al., 
2012; Schairer et al., 2012), the application of NO-releasing scaffolds for the 
treatment of periodontitis represents an unexplored opportunity.
The design of macromolecular scaffolds (e.g., dendrimers, silica, poly-
mers) capable of storing and delivering biocidal levels of NO is crucial to the 
application of gaseous NO as an antimicrobial therapy (Carpenter and 
Schoenfisch, 2012; Riccio and Schoenfisch, 2012). Previously, we have syn-
thesized N-diazeniumdiolated silica and dendrimer scaffolds capable of spon-
taneous NO release under biological conditions as potential in vivo 
antimicrobial agents (Shin et al., 2007; Sun et al., 2012). The antimicrobial 
activity of such scaffolds was demonstrated against several Gram-positive, 
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Gram-negative, and antibiotic-resistant bacteria (Hetrick et al., 
2008; Sun et al., 2012) as well as biofilms (Hetrick et al., 2009; 
Lu et al., 2013). Collectively, this prior work suggests exoge-
nous NO delivered via macromolecular NO-release scaffolds 
may prove useful against dental microbes, including those orga-
nized within supragingival and subgingival biofilms.
Herein, we investigated the bactericidal efficacy of 
NO-releasing 3-methylaminopropyltrimethoxysilane (MAP3) 
silica particles and propylene oxide (PO)-modified generation 1 
(G1) poly(amidoamine) (PAMAM) dendrimers against cario-
genic bacteria (Streptococcus mutans and Streptococcus sanguinis) 
and periodontopathogens (Aggregatibacter actinomycetemcom-
itans and Porphyromonas gingivalis). The cytotoxicity of the 
NO-release scaffolds to human gingival fibroblasts (HGF-1) 
was also evaluated and compared with CHX to ascertain the 
therapeutic potential of these materials for oral care.
MAtErIAls & MEthODs
synthesis of nitric Oxide release scaffolds
We prepared N-diazeniumdiolate NO donor-modified proline by 
dissolving 2.05 g proline and 2.00 g of sodium methoxide in 
25 mL methanol. After brief mixing, this solution was placed in 
a Parr reaction bottle (Saavedra et al., 1996). The bottle was 
purged with argon (Ar) and subsequently pressurized with NO 
gas (10 bar). After 3 days of constant stirring, the bottle was 
purged again with Ar, and the solution was treated with cold 
ether to precipitate the N-diazeniumdiolate-modified product. 
The NO donor (“PROLI/NO”) was collected by vacuum filtra-
tion, washed with cold ether, and stored at -20°C.
Hybrid tetramethyl orthosilicate (TMOS) (Sigma, St. Louis, 
MO, USA) MAP3 (Gelest, Morrisville, PA, USA) particles were 
synthesized by the injection of a solution containing 0.538 mL 
TMOS and 1.68 mL MAP3 into a flask containing 60.1 mL etha-
nol, 27.8 mL water, and 9.8 mL ammonium hydroxide (30 wt%) 
(Shin et al., 2007). This solution was stirred for 2 hr under ambi-
ent conditions and then centrifuged at 2900 x g at 4°C for 10 min. 
Particles were collected by decanting the supernatant. The pellet 
was re-suspended in ethanol, centrifuged, and decanted twice 
more to remove unreacted silanes and residual solvent. The result-
ing amine-functionalized MAP3 particles (70 mol% aminosilane) 
were dried under vacuum, and a portion (30 mg) was suspended 
in 6 mL 9:1 N,N-dimethylformamide (DMF) and methanol. This 
solution was sealed in a Parr bottle containing 50 µL sodium 
methoxide (5.4 M in methanol). The bottle was flushed with Ar to 
remove oxygen and pressurized to 10 bar NO. After 3 days of 
constant stirring, the bottle was again flushed with Ar to remove 
unreacted NO. The particles were re-collected by centrifugation 
and decanting of supernatant. The pellet was re-suspended in 
ethanol, centrifuged, and decanted twice more to remove residual 
solvent and sodium methoxide. Particles were dried under vac-
uum, vacuum-sealed, and stored at –20°C to yield 
N-diazeniumdiolate NO donor-modified MAP3 silica.
Secondary amine-functionalized G1 PAMAM dendrimers 
were synthesized by the dissolution of primary amine-function-
alized G1 dendrimers (100 mg) in methanol (1 mL) with 39.2 µL 
propylene oxide (PO) (Lu et al., 2013). After 3 days of constant 
stirring, the solvent was removed under vacuum to yield 
PO-modified PAMAM dendrimers. Sodium methoxide (51.8 µL; 
5.4 M in methanol) was then added to 45 mg of dendrimers in 
methanol (1 mL), and the resulting solution was placed in a Parr 
bottle, sealed, flushed with Ar, and filled with NO (10 bar). After 
3 days of constant stirring, the bottle was purged with Ar again to 
remove unreacted NO. The NO-releasing G1-PAMAM-PO den-
drimers were then stored at -20°C.
characterization of nitric Oxide release
A Sievers 280i Chemiluminescence Nitric Oxide Analyzer 
(Boulder, CO, USA) was used to quantify NO release at 37°C 
(Coneski and Schoenfisch, 2012). The NO-releasing material 
(~1 mg) was added to a flask containing 30 mL deoxygenated 
phosphate-buffered saline (PBS; pH = 7.4). Nitrogen was used 
to purge this solution continuously and thus carry liberated NO 
to the analyzer (flow rate, 80 mL/min). The NO analysis was in 
real time and continued until the NO levels fell below 10 ppb.
bacteria-killing Assays
Streptococcus mutans (ATCC #25715), Streptococcus sanguinis 
(ATCC #49297), and Aggregatibacter actinomycetemcomitans 
(ATCC #43717) were purchased from the American Type Tissue 
Culture Collection (Manassas, VA, USA). Porphyromonas gin-
givalis strain A7436 was provided by the UNC School of 
Dentistry, Chapel Hill, NC. Stock cultures, initially stored in 
15% (v/v) glycerol in PBS at -80°C, were grown overnight in 
brain heart infusion (BHI) broth at 37°C or Difco anaerobic 
broth for P. gingivalis. A 500-µL aliquot of this solution was re-
inoculated into 50 mL fresh broth, incubated at 37°C, and grown 
to 108 colony-forming units per milliliter (CFU/mL). S. mutans 
and S. sanguinis were cultured aerobically. A. actinomycetem-
comitans was cultured in a microaerophilic environment (6% -16% 
O2 and 2%-10% CO2) in a GasPak EZ Campy Container System 
(Becton, Dickinson and Company; Franklin Lakes, NJ, USA). 
P. gingivalis was cultured anaerobically in an atmosphere of 5% 
CO2, 10% H2, and 85% N2.
We quantified the antimicrobial activity of the NO-releasing 
materials against planktonic cultures of bacteria by determining 
the minimum bactericidal concentration (MBC2h) required to 
achieve a 3-log reduction in viability after 2 hr. Bacteria (108 
CFU/mL) were re-suspended in tris(hydroxymethyl)amino-
methane phosphate-buffered saline solution (Tris-PBS; pH = 
7.4) and diluted to 106 CFU/mL. This bacteria solution was 
added to vials containing NO-releasing material and respective 
controls, sonicated or vortexed briefly, and incubated at 37°C 
with shaking. After 2 hr, these solutions were diluted and spiral-
plated on BHI agar or Wilkins-Chalgren agar for P. gingivalis. 
Agar plates containing S. mutans and S. sanguinis were incu-
bated aerobically for 72 hr. A. actinomycetemcomitans plates 
were incubated under microaerophilic conditions for 48 hr. 
P. gingivalis plates were incubated for 96 hr under anaerobic 
conditions.
cytotoxicity Evaluation
Human gingival fibroblasts (HGF-1) (ATCC #CRL-2014) 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
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containing 10% v/v fetal bovine serum and 1 wt% penicillin/ 
streptomycin under 5% CO2 and humidified conditions at 37°C. 
After reaching confluence, cells were trypsinized and seeded 
onto a 96-well plate. The NO-release scaffolds or controls were 
added to the wells. Following incubation for 2 hr at 37°C, the 
supernatant was aspirated, and DMEM, phenazine methosulfate 
(PMS) (100/20/1, v/v/v), and [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
(MTS) were added to the wells. After incubation for an addi-
tional 2 hr at 37°C, solutions were transferred to a microtiter 
plate for absorbance measurement at 490 nm. Cell viability was 
quantified with respect to untreated cells and subtraction of 
blanks. The cytotoxicity of chlorhexidine was evaluated similarly.
rEsults
Nitric oxide-release half-life (t1/2), maximum NO flux ([NO]m), 
and total NO release over 2 hr (t[NO]2h) were determined for the 
3 NO donor systems (Table). Of note, t[NO]2h represents the NO 
dose delivered during the MBC2h bacterial killing assay. Of the 
3 NO donors, N-diazeniumdiolate-modified proline (PROLI/
NO) had the largest NO payload (6.29 ± 0.24 µmol/mg) and 
fastest NO release (t1/2 of 2.3 ± 0.1 min). The t[NO]2h and t[NO] 
for PROLI/NO were equal, since the NO release is exhausted 
within 10 min. Compared with PROLI/NO, the silica particles 
released less NO (t[NO]2h = 0.81 ± 0.15 µmol/mg) and did so 
more slowly (t1/2 = 19.8 ± 3.3 min). Despite releasing an equiva-
lent level of NO (t[NO]2h = 0.77 ± 0.11 µmol/mg) vs. the silica, 
the dendrimer system exhibited the slowest NO release (t1/2 = 
43.8 ± 4.3 min).
With respect to bactericidal efficacy (MBC2h), a 3-log reduc-
tion in viability was observed for A. actinomycetemcomitans at 
4 mg/mL in NO-releasing silica or PROLI/NO (Fig. 1). These 
scaffold concentrations corresponded to NO doses of 3.2 and 
25.2 µmol/mL, respectively (Fig. 1). Less NO-releasing den-
drimer was required for analogous killing (MBC2h = 2 mg/mL; 
NO dose = 1.5 µmol/mL). P. gingivalis proved even more sensi-
tive to NO treatment, with a 3-log reduction in viability 
observed at 0.5, 1, and 2 mg/mL for NO-releasing proline, den-
drimers, and silica, corresponding to NO doses of 3.1, 0.8, and 
1.6 µmol/mL, respectively. In contrast, cariogenic Streptococcus 
species were less susceptible to NO-releasing silica, with no 
observed 3-log killing up to 64 mg/mL. As shown in Fig. 2, 
similarly large concentrations of NO-releasing proline and 
dendrimers (48 mg/mL) were required to kill S. mutans (NO 
doses of 301.9 and 37.0 µmol/mL, respectively). Likewise, 
S. sanguinis required 32 and 48 mg/mL PROLI/NO and 
NO-releasing dendrimers, respectively (NO doses of 201.3 and 
37.0 µmol/mL).
Both NO-releasing dendrimers and silica showed reductions 
in HGF-1 viability (75 ± 3 and 61 ± 12% compared with 
untreated cells) at the maximum concentrations required to kill 
periodontopathogens (2 and 4 mg/mL, respectively), but only 
minimally when compared with chlorhexidine (Fig. 3). In con-
trast, PROLI/NO was more toxic to HGF-1 at the maximum 
concentration required to kill periodontopathogens (18 ± 2% 
compared with untreated cells for 4 mg/mL). Likewise, 0.12 and 
0.20% (w/w) chlorhexidine (CHX) negatively affected HGF-1 
viability (17 ± 2 and 22 ± 3% compared with untreated cells, 
respectively).
DIscussIOn
This study examined the antimicrobial efficacy of macromolecular 
NO-release scaffolds against 4 microbes affecting oral health 
(S. mutans, S. sanguinis, A. actinomycetemcomitans, and P. gingi-
valis). While NO release from macromolecular scaffolds has 
proven effective against Candida, Escherichia, Pseudomonas, 
and Staphylococcus species (Hetrick et al., 2008; Sun et al., 
2012), its efficacy against dental micro-organisms and the 
impact of NO-release scaffold on antibacterial activity are unex-
plored topics. Although prior research has indicated salivary 
nitrite-derived NO as a means to inhibit cariogenic and peri-
odontopathogenic growth (Silva Mendez et al., 1999; Allaker 
et al., 2001), our work is the first to evaluate the effects of exog-
enous NO delivered via macromolecular scaffolds against peri-
odontopathogens. Similar to an earlier study showing enhanced 
action against Gram-negative species (Hetrick et al., 2008), NO 
treatment was highly effective against A. actinomycetemcomi-
tans and P. gingivalis. The NO-releasing dendrimers possessed 
superior bactericidal activity compared with silica, even though 
they released similar amounts of NO (t[NO]2h). Indeed, less NO 
was required to eradicate A. actinomycetemcomitans (1.5 vs. 
3.2 µmol/mL for dendrimer and silica, respectively) and P. gin-
givalis (0.8 vs. 1.6 µmol/mL for dendrimer and silica, respec-
tively) because of enhanced bacterial association of the dendritic 
scaffold (Sun et al., 2012). Despite storing and releasing more 
NO, similar concentrations of PROLI/NO were required to kill 
periodontopathogens, albeit at larger NO levels (3.1 and 25.2 
µmol/mg for P. gingivalis and A. actinomycetemcomitans, 
respectively). This result would be expected, since the PROLI/ 
NO produces NO without bacteria association—and thus 
table. Characterization of NO-releasing Materials by Means of a Chemiluminescent Nitric Oxide Analyzer
NO Release Scaffold t[NO] (µmol/mg) [NO]m (ppb/mg) t ½ (min) t[NO]2h (µmol/mg)
70 mol% MAP3 0.84 ± 0.14 9200 ± 4300 19.8 ± 3.3 0.81 ± 0.15
G1-PAMAM-PO 0.96 ± 0.11 2900 ± 800 43.8 ± 4.3 0.77 ± 0.11
Proline 6.29 ± 0.24 370000 ± 11000 2.3 ± 0.1 6.29 ± 0.24
Results shown for particles (70 mol% MAP3), dendrimers (G1-PAMAM-PO), and small-molecule NO donor (NO-releasing proline). Values pre-
sented as means ± standard deviations. For all measurements, n = 3 or more pooled experiments.
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Figure 2. Bactericidal efficacy of (A) 70 mol% MAP3 particles, (b) G1-PAMAM-PO dendrimers, and (c) proline against S. mutans in Tris-PBS after 
2 hr. Bactericidal efficacy of (D) 70 mol% MAP3 particles, (E) G1-PAMAM-PO dendrimers, and (F) proline against S. sanguinis in Tris-PBS after 
2 hr. NO-releasing material denoted by rectangles (--) and non-NO-releasing controls denoted by circles (-•-). Error bars signify standard deviation 
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Figure 1. Bactericidal efficacy of (A) 70 mol% MAP3 particles, (b) G1-PAMAM-PO dendrimers, and (c) proline against A. actinomycetemcomitans 
in Tris-PBS after 2 hr. Bactericidal efficacy of (D) 70 mol% MAP3 particles, (E) G1-PAMAM-PO dendrimers, and (F) proline against P. gingivalis in 
Tris-PBS after 2 hr. NO-releasing material denoted by rectangles (--) and non-NO-releasing controls denoted by circles (-•-). Error bars signify 
standard deviation of the mean viability (CFU/mL). For all measurements, n = 3 or more pooled experiments.
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indiscriminately—whereas the macromolecular scaffolds associ-
ate with bacteria and localize (i.e., target) the NO (Hetrick et al., 
2008). The efficient killing of A. actinomycetemcomitans and 
P. gingivalis with dendrimers or silica illustrates the advantage 
of macromolecular NO-release scaffolds over small-molecule 
NO donors for delivering bactericidal levels of NO.
As evidenced by the larger NO-donor scaffold concentra-
tions and NO doses required for equivalent killing, S. mutans 
and S. sanguinis were less sensitive to treatment with NO. While 
these bacteria are Gram-positive species with a thicker peptido-
glycan layer, the substantial disparity in bactericidal efficacy 
relative to periodontopathogens was surprising and has not been 
previously observed. Of note, S. mutans makes use of nitrite 
reductase, an enzyme that converts nitrite to NO, to facilitate 
survival in nitrite-rich, acidic environments (Choudhury et al., 
2007). Gusarov and Nudler reported that NO facilitates protec-
tion against oxidative stress (“NO-mediated cytoprotection”) in 
Bacillus subtilis (Gusarov and Nudler, 2005), and this may be 
observed for other Gram-positive species. In this respect, 
S. mutans and S. sanguinis may tolerate NO because of its role 
as a metabolite rather than a biocidal agent.
Compared with chlorhexidine at 0.12 and 0.20% (w/w)—
concentrations used clinically—the toxicities of the NO-releasing 
dendrimers and silica to human gingival fibroblasts were mini-
mal (Fig. 3) at the maximum concentrations required to kill 
periodontopathogens (2 and 4 mg/mL). In contrast, substantial 
toxicity was observed for PROLI/NO at the maximum concen-
tration to kill periodontopathogens (4 mg/mL). This result is 
attributed to both the magnitude (25.2 µmol/mL) and the rapid 
nature of the NO release from this small-molecule NO donor. 
Hetrick et al. noted similar toxicity to L929 murine fibroblasts 
for PROLI/NO concentrations ≥ 5 mg/mL (Hetrick et al., 2008). 
As expected, the relative toxicity for all of the NO donor sys-
tems was greater at concentrations required for complete eradi-
cation of the cariogenic bacteria (S. mutans and S. sanguinis).
The sharp disparity in NO susceptibility between the 2 
classes of oral microbes investigated herein suggests the utility 
of NO-releasing macromolecular scaffolds as potential therapies 
for periodontal disease. While S. mutans and S. sanguinis are 
cariogenic, caries-associated bacteria, A. actinomycetemcomi-
tans and P. gingivalis are periodontopathogens linked to peri-
odontal disease (Silva et al., 2012). In this manner, NO-releasing 
macromolecular scaffolds may prove useful in killing periodon-
topathogenic Gram-negative bacteria over Gram-positive cario-
genic micro-organisms. Although the concept of therapeutics to 
kill periodontopathogens is appealing, methods for delivering 
antimicrobials locally without fostering antibiotic resistance and 
substantial toxicity to mammalian cells remain elusive. 
Macromolecular NO-release scaffolds represent a potential 
strategy for achieving this goal. Future work must evaluate the 
antibacterial activity of these NO-release scaffolds against other 
dental microbes to validate the proposed enhanced sensitivity of 
periodontopathogens over cariogenic oral microbes to NO treat-
ment. The efficacy of these NO-release scaffolds against bacte-
rial biofilms of both periodontopathogens and cariogenic 
microflora must also be examined, since plaque is a complex 
biofilm. Last, in vivo models of periodontal disease must be 
used to elucidate the full potential of NO release as an effective 
adjuvant therapy.
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